Ultragenyx Q2 FY26 net loss narrows to $92 million; revenue rises to $214 million
RARE•Expenses and cash position
Operating expenses grew to $289 million from $275 million.
Cash, cash equivalents, and marketable securities totaled $436 million at June 30.
Guidance and pipeline updates
Ultragenyx reaffirmed 2026 revenue guidance of $730 million-$760 million, excluding potential new launches, and targets profitability in 2027.
The FDA set PDUFA dates for DTX401 on Aug. 23, 2026, and UX111 on Sept. 19, 2026. Phase 3 Aspire data for GTX-102 is expected in September or October.
Quarterly revenue rises and net loss narrows
Ultragenyx Q2 revenue rose 28.14% to $214 million, while net loss narrowed to $92 million from $115 million.
Crysvita revenue increased to from , and Dojolvi revenue climbed to from .
